期刊文献+

临床使用静脉注射免疫球蛋白的适宜性评价标准 被引量:4

Suitability evaluation standards for the administration of intravenous immunoglobulin
暂未订购
导出
摘要 目的:制定临床使用静脉注射免疫球蛋白(intravenous immunoglobulin,IVIG)的适宜性评价标准,为临床医师制定治疗方案及临床药师对临床使用IVIG的专项点评提供评价依据。方法:检索国际现有专项IVIG使用指南,对其间存在的不完全一致现象进行判断及综合分析,对其推荐级别进行判定。结果:制定出临床使用IVIG的推荐类别(获准适应证、推荐-获益、酌情-获益多、酌情-获益少、不支持使用)、选用指征、剂量、疗程等作为适宜性评价标准。结论:确立较适宜且可操作性的临床使用IVIG的适宜性评价表,为临床医师制定治疗方案及临床药师对IVIG临床使用专项点评提供评价依据。 Objective:To develop the suitability evaluation standards for the administration of intravenous immunoglobulin(IVIG),which would provide sound basis for clinicians to work out proper treatment protocols,and good evidence for clinical pharmacists to make special evaluations on the administration of IVIG.Methods:Through retrieval of current special IVIG guidelines,judgment and comprehensive analysis were made on the inconsistency that might exist,and finally the recommended levels were determined.Results:Recommended categories of IVIG(licensed indications,recommended benefit,discretionbenefit more,discretion-benefit less,no support)for the administration,selected indications,dosage and course of treatment etc.were used as the suitability evaluation standards.Conclusion:Operable suitability evaluation standards were established for the administration of IVIG.It could provide good evidence both for clinicians to develop proper treatment protocols and clinical pharmacists to make special evaluations on the administration of IVIG.
作者 李玥
出处 《药学服务与研究》 CAS CSCD 2013年第3期177-182,共6页 Pharmaceutical Care and Research
关键词 静脉注射免疫球蛋白 适应证 评价标准 指南 intravenous immunoglobulin indications evaluation standards guidelines
  • 相关文献

参考文献10

  • 1Delforge M, Farber C M, Spfith P,etal. Recommended indi- cations for the administration of polyclonal immunoglobulin preparations[J]. Acta Clin Belg,2011,66(5) :346-360.
  • 2Provan D,Chapel H M, Carrock Sewelll W A, etal. Prescri bing intravenous immunoglobulin: summary of Department of Health Guidelines[J]. BMJ,2008,337 : 990-992.
  • 3Orange J S, Hossny E M, Weiler C R, etal. Use of intrave- nous immunoglobulin in human disease: a review of evidence by members of the Primary lmmunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology [-J]. J Allergy Clin Imnmnol, 2006,117 (4 Suppl) : S525-S553.
  • 4Anderson D, All K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic condi- tions[J]. Transfus Med Rev,2007,21(2 Suppl 1):S9- S56.
  • 5Robinson P, Anderson D, Brouwers M, et al. Evidence- based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions[J]. Transfus Med Rev,2007,21(2 Suppl 1) :S3-S8.
  • 6National Blood Authority of the Australian Government. Cri- teria for the clinical use of intravenous immunoglohulin in Australia (2nded). Canberra: NBA; 2012[EB/OL].[2013- 03 -20]. http://www, nba. gov. au/ivig/pdf/criteria, pdf.
  • 7Rink B D, Gonik B, Chmait R H, etal. Maternal hemolysis after intravenous immunoglohulin treatment in fetal and neo natal alloimmune thrombocytopenia [ J ]. Obstet Gynecol, 2013,121(2 Pt 2 Suppl 1):471-473.
  • 8Caress J B, Hobson-Webb L, Passmore L V, et al. Case- control study of thromboembolic events associated with IV immunoglobulin[J]. J Neurol,2009,256(3) :339 -342.
  • 9Mullane D, Williams L, Merwick A, et al. Drug induced aseptic meningitis caused by intravenous immunoglohulin therapy[J]. Ir Med J,2012,105(6) :182- 183.
  • 10Pierce L R, Jain N. Risks associated with the use of intrave- nous immunoglobulin[Jl. Transfus Med Rev, 2003,17 (4) : 241- 251.

同被引文献49

引证文献4

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部